Both Europe and Japan have rejected the US's continuations approach

I came across a very interesting perspective on the US claims and continuations debate posted on Holman’s Biotech IP Blog. Basically, it seems to be saying that the JPO and the EPO have had cause to look at claims and continuations in recent years,…

Get unlimited access to all IAM content